A groundbreaking new drug for lower back pain, using antibiotics, shows significant promise in early trials.
Six out of ten participants experienced substantial pain and disability reduction, offering hope to millions.
Developed by Persica Pharmaceuticals, the drug, PP353, targets the infection causing the pain, not just the symptom.
Further trials are needed before widespread availability, but initial results suggest a potential game-changer.
